Marshall Wace North America’s Aridis Pharmaceuticals Inc. Common Stock ARDS Stock Holding History

Marshall Wace North America’s Portfolio ARDS Stock Details ARDS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-19	Closed	–	–	1740
2019 Q1	$0	Buy	+19	New	+$176	﹤0.01%	1994

Other funds holding ARDS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Marshall Wace North America's ARDS Position: Q2 2019 in Review

Marshall Wace North America sold out of Aridis Pharmaceuticals Inc. Common Stock (ARDS) in Q2 2019, closing a stake of 19 shares.

Marshall Wace North America first reported a position in ARDS in Q1 2019 and held it in 1 quarter. The position peaked at $0 in Q1 2019. 6 funds tracked by Wall St. Rank hold ARDS as of Q2 2019.

Marshall Wace North America reported no remaining Aridis Pharmaceuticals Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
Marshall Wace North America sold 19 Aridis Pharmaceuticals Inc. Common Stock shares in Q2 2019.
Marshall Wace North America first reported a position in Aridis Pharmaceuticals Inc. Common Stock in Q1 2019 and held it in 1 quarter.
Marshall Wace North America's Aridis Pharmaceuticals Inc. Common Stock position peaked at $0 in Q1 2019.
6 funds tracked by Wall St. Rank held Aridis Pharmaceuticals Inc. Common Stock as of Q2 2019.

Based on Marshall Wace North America's 13F filing for Q2 2019, filed 14 Aug 2019.